Zhou, Hang http://orcid.org/0000-0002-7694-6391
Kalayasiri, Rasmon
Sun, Yan
Nuñez, Yaira Z.
Deng, Hong-Wen http://orcid.org/0000-0002-0387-8818
Chen, Xiang-Ding
Justice, Amy C.
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Chang, Suhua http://orcid.org/0000-0001-7465-3985
Lu, Lin http://orcid.org/0000-0003-0742-9072
Shi, Jie http://orcid.org/0000-0001-6567-8160
Sanichwankul, Kittipong
Mutirangura, Apiwat
Malison, Robert T.
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Funding for this research was provided by:
Brain and Behavior Research Foundation (27835)
Biomedical Laboratory Research and Development, VA Office of Research and Development (#I01BX003341, #I01BX003341)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA037974, R01 DA037974)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 20 September 2021
Revised: 22 December 2021
Accepted: 29 December 2021
First Online: 29 January 2022
Competing interests
: HRK is a member of a scientific advisory board for Dicerna Pharmaceuticals and a consultant to Sophrosyne Pharmaceuticals and Sobrera Pharmaceuticals and is a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last 3 years by AbbVie, Alkermes, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences. HRK and JG are named as inventors on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. The remaining authors have nothing to disclose.